Ixcela, Inc.
Classification
Private
Financials
Revenue & Profit
Valuation
Ratios
People
Deals
M&A2024-03-15Completed
Investor Sponsors NorthBridge PE | Stake Tags 100% |
Deal Amount $120M | Is PE deal Yes |
Target Company Valuation $1.20 MM | Is deal PE backed Yes |
Techniques Acquisition of Assets, Taken Private | Total Acquired 100% |
Investor Sponsors
Deal Amount
$120M
Target Company Valuation
$1.20 MM
Techniques
Acquisition of Assets, Taken Private
Stake Tags
100%
Is PE deal
Yes
Is deal PE backed
Yes
Total Acquired
100%
Secondary Transaction2023-09-01Canceled
Investor Sponsors -- | Stake Tags Majority |
Deal Amount Undisclosed | Is PE deal No |
Target Company Valuation -- | Is deal PE backed Yes |
Techniques Secondary Sale, Management Buy-out (MBO) | Total Acquired 65% |
Investor Sponsors
--
Deal Amount
Undisclosed
Target Company Valuation
NaN
Techniques
Secondary Sale, Management Buy-out (MBO)
Stake Tags
Majority
Is PE deal
No
Is deal PE backed
Yes
Total Acquired
65%
Funding
About
About
Ixcela, Inc. is a privately-held biotech company intended to improve internal fitness. The company identifies key small molecules associated with gut microbiome imbalances and develops individualized therapy to restore these molecules to their proper levels with a personalized program that includes proprietary supplements, as well as personalized nutrition and fitness plans, enabling individuals to address common health issues such as irritable bowel syndrome, acid reflux, and leaky gut. Ixcela, Inc. was founded in 2012. Ixcela, Inc. headquarters are located in Bedford, Massachusetts.
Keywords
Keywords
Classified
Private